Grants, Giving & Corporate Sponsorship Support
Bristol-Myers Squibb is committed to supporting appropriate independent requests for funding and in-kind support to non-profit third party Organisations which make a difference in people’s lives either directly or indirectly through healthcare related support, medical and scientific education, research and general community based charitable activities.
Listed below are some of the various type of initiatives which Bristol-Myers Squibb may support.
- Charitable Donations and in-kind Support
- Independent Medical Education
- Scholarship Support
- Fellowship Support
- Patient Education Grant
- Corporate Sponsorship for events, activities and initiatives which contribute to scientific exchange, or demonstrate a commitment to patients or communities
- Umbrella Research Grants (Funds provided to an institution/organisation to support scientific research programs in a broad area related to a Bristol-Myers Squibb therapeutic area of interest). Umbrella Research Grants are distinct from Investigator Sponsored Research - ISRs.
The Application Process
In order to be considered, Organisations will need to meet Bristol Myers Squibb internal business conduct and ethics criteria as embodied in the BMS “Principles of Integrity”, together with the Irish Pharmaceutical Healthcare Association (IPHA), the Health Products Regulatory Agency (HPRA) Regulations, as well as other relevant Legal and Regulatory requirements.
Unfortunately, not all requests can be met, but we will assess each application on its merits and will prioritise those requests which are aligned to our therapy areas and focus on supporting scientific and non-profit and charitable organisations who directly support a commitment to improving the lives of patients and ongoing medical and scientific research and education.
[As a general rule, we are not able to support requests from individuals for their personal ongoing education].
Ready to Apply?
Submit your application today.
Learn How on Our U.S. Corporate Website
Date of preparation: May 2018; MLTUK1701479-01